Skip to main content
. 2014 Sep 8;9(9):e107276. doi: 10.1371/journal.pone.0107276

Figure 2. Relapse-free survival and overall survival in patients with NSCLC.

Figure 2

EGFR and KRAS mutation status were not associated with relapse-free survival (P = 0.600) or overall survival (P = 0.873) in lung adenocarcinoma; c–d. Lymphnode stage (N stage) was significantly associated with relapse-free survival (P = 0.001) or overall survival (P = 0.001) in NSCLC.